Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Osteoclast-mediated bone resorption is the process by which osteoclasts break down bone tissue, releasing minerals and degrading the organic matrix. It is essential for bone remodeling and calcium homeostasis but contributes to diseases like osteoporosis when dysregulated. The process involves osteoclast differentiation, attachment to bone, acidification of the resorption lacuna, enzymatic degradation of bone matrix, and phagocytosis of degradation products. Regulation is achieved through hormones, cytokines, and interactions with osteoblasts. Therapeutic strategies target osteoclast differentiation, activation, enzymatic function, and survival.
Inhibition of osteoclast differentiation, activation, or function; modulation of bone remodeling balance.
4 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Osteoclast-mediated bone resorption.